-
Mashup Score: 3
Immune engager therapies, if available, should be considered as a first treatment choice following idecabtagene vicleucel treatment in multiple myeloma, according to Murali Janakiram, MD, MS.
Source: www.cancernetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Immune engager therapies, if available, should be considered as a first treatment choice following idecabtagene vicleucel treatment in multiple myeloma, according to Murali Janakiram, MD, MS.
Source: www.cancernetwork.comCategories: General Medicine News, Hem/OncsTweet-
RT @CAR_TCell: Immune Cell Engagers Show Real-World Responses in Relapsed Multiple Myeloma: https://t.co/EsFXUknXJ1 #CARTCR
-
-
Mashup Score: 4GC012F CAR T Shows 100% Complete Response Rate in Multiple Myeloma - 7 month(s) ago
Researchers presented updated results from longer-term follow-up studies of GC012F for newly-diagnosed multiple myeloma treatment at the International Myeloma Society Annual Meeting.
Source: www.targetedonc.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @CAR_TCell: GC012F CAR T Shows 100% Complete Response Rate in Multiple Myeloma: https://t.co/Si8AfNX14X #CARTCR
-
-
Mashup Score: 2(1) Post | Feed | LinkedIn - 8 month(s) ago
Feed post Mark Flower • 3rd+ VP Business Development | Cell Therapy Enthusiast 1h • Edited • …
Source: www.linkedin.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Great opening panel at #CARTCR, thanks to Adrian Bot for leading the discussion. @NovartisScience @KitePharma @CHOPCancerCntr https://t.co/NTPFWkjb0U
-
-
Mashup Score: 2Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change - 10 month(s) ago
Medicare pays so little for pricey CAR-T cancer drugs that hospitals sometimes lose money providing them. But that could soon change.
Source: www.statnews.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @CAR_TCell: Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change: https://t.co/JsTXUM7Qhp #CARTCR #…
-
-
Mashup Score: 08th CAR-TCR Summit | August 29 - September 1 | Boston, MA - 11 month(s) ago
Full 2023 Agenda available now! Click here to see all 200+ speakers, full session details across 8 tracks of content, and more.
Source: CAR-TCR Summit 2023Categories: Future of Medicine, Latest HeadlinesTweet-
Join the 8thCAR-TCR Summit in Boston this year to meet 1000+ industry experts across 4 days and 8 streams discussing all things CAR-T, from early discovery through to commercialization. Lean more here: https://t.co/tbyu0N7nmK #CARTCR
-
-
Mashup Score: 4
A team of researchers at KAIST said on Thursday that they developed a treatment for second-generation T cell receptor-engineered T cells (TCR-T) that overcome the tumor microenvironment for solid cancers where the immune system is suppressed.First-generation chimeric antigen receptor T cells, abbrev
Source: KBRCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @CAR_TCell: KAIST scientists use CRISPR to develop TCR-T immunotherapy for solid cancers: https://t.co/TBKhJlnkvL #CARTCR #immunotherapy
-
-
Mashup Score: 0The Multiple Myeloma Daily - 1 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/TWgRLzoWvL Thanks to @PBeatingCancer @CAR_TCell #dvt #cartcr
-
-
Mashup Score: 2
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @CAR_TCell: Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure: https://t.co/iALoQo7fPY #CARTCR #immunotherapy
-
-
Mashup Score: 6
Local administration of chimeric antigen receptor T cells via a fibrin-based gel effectively eliminated leftover cancer cells after incomplete surgical resection, study results published in Science Advances showed. Researchers evaluated the safety and efficacy of a mesothelin-targeted CAR-T construct and delivery method against pancreatic ductal adenocarcinoma and triple-negative breast cancer
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @CAR_TCell: Researchers use CAR-T gel to kill leftover cancer cells after surgery: https://t.co/pXglwDHKI4 #CARTCR #immunotherapy
-
RT @CAR_TCell: Immune Cell Engagers Show Real-World Responses in Relapsed Multiple Myeloma: https://t.co/EsFXUknXJ1 #CARTCR